Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19

COVID-19 Clinical Trial

Official title:

A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (Calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected With SARS-CoV-2 (REsCue)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04551911
• Other study ID #: CTAP101-CL-2014
• Status: Completed
• Phase: Phase 2
• Start date: November 2, 2020
• Est. completion date: October 8, 2021

Study information

• Verified date: May 2024
• Source: OPKO Health, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 2, single or multi-center, randomized, double-blind placebo-controlled study to evaluate the safety and efficacy of Rayaldee (CTAP101 Capsules) to treat adult subjects with mild to moderate COVID-19 who test positive for SARS-CoV-2.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 171
• Est. completion date: October 8, 2021
• Est. primary completion date: October 8, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female =18 years of age

2. Confirmed within the past 3 days to have SARS-CoV-2 infection as evidenced by a positive nasopharyngeal swab test using RT-PCR or any substitutable FDA-authorized diagnostic test

3. Confirmed to have only mild or moderate COVID-19 based on the first of the patient reported scores obtained during screening which meets the criterion a FLU-PRO Plus© score of = 1.5 for each of the chest/respiratory and body/systemic domains, and the absence of clinical signs indicative of more severe disease (eg, oxygen saturation < 94% on room air or respiration rate > 30 bpm)

4. Represents on self-assessment that the current COVID-19 symptoms are not consistent with usual health and that they are the same or worse than on the previous day

5. Willing to limit the use of vitamin D therapies or supplements except for normally fortified food products (eg, milk) during the course of the 6-week study

6. Must demonstrate the ability to comply with all study requirements

7. Must be without any disease state or physical condition that might impair evaluation of safety or which, in the investigator's opinion, would interfere with study participation.

Exclusion Criteria:

1. Clinical signs indicative of severe or critical COVID-19 disease (eg, oxygen saturation < 94% on room air or respiration rate > 30 bpm)

2. Pregnant or lactating women who are breastfeeding

3. Use of systemic glucocorticoid medications in the last six months

4. Recent history (previous 12 months) of primary hyperparathyroidism, kidney stones, hypercalciuria and/or hypercalcemia

5. History of a chronic granuloma-forming disease (eg, sarcoidosis)

6. History of tuberculosis or histoplasmosis

7. History of chronic liver disease

8. History (previous 12 months) of cardiac event indicative of chronic cardiovascular diseases including congestive heart failure, poorly controlled hypertension and arrhythmias

9. History in the past five years of multiple myeloma or carcinoma of the breast, lung or prostate

10. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of vitamin D or 25-hydroxyvitamin D (25D) (eg, small bowel resection, history of Crohn's disease or ulcerative colitis)

11. Ongoing treatment with thiazide diuretics

12. History of hyperphosphatemia, hyperuricemia and gout

13. Renal impairment measured as eGFR< 15 mL/min/1.73m² on serum creatinine in the last three months

14. Serum calcium =9.8 mg/dL in the last three months

15. Evidence of existing or impending dehydration

16. Known or suspected to have hypersensitivity to any of the constituents of the study drug

17. Currently participating in, or have participated in, an interventional/investigational study within 30 days prior to study screening.

Related Conditions & MeSH terms

• Coronavirus
• COVID-19
• SARS-CoV2 Infection

Intervention

Drug:
• Rayaldee
30 mcg calcifediol Extended-Release (ER) Capsule
• Placebo
0 mcg calcifediol Extended-Release (ER) Capsule

Locations

Country	Name	City	State
United States	OPKO Investigative Site	Brookhaven	Mississippi
United States	OPKO Investigative Site	Evanston	Illinois
United States	OPKO Investigative Site	Farmington Hills	Michigan
United States	OPKO Investigative Site	Jackson	Michigan
United States	OPKO Investigative Site	Laurel	Maryland
United States	OPKO Investigative Site	Miami	Florida
United States	OPKO Investigative Site	Miami	Florida
United States	OPKO Investigative Site	Omaha	Nebraska
United States	OPKO Investigative Site	San Francisco	California
United States	OPKO Investigative Site	Sterling Heights	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
OPKO Health, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Concentration of Serum Total 25-hydroxyvitamin D Attained at or Above 50 ng/mL at Visit 3 (Day 14).	Number and percentage of subjects with serum total 25-hydroxyvitamin D attained at or above 50 ng/mL at Visit 3 (Day 14)	14 days
Primary	Resolution of COVID-19 Five Aggregated Symptoms Using the Flu-PRO Plus© Questionnaire.	The FLU- PRO Plus© questionnaire was specifically designed and validated to evaluate in clinical trials the presence, severity and duration of symptoms associated with viral infections. It contains 32 items (eg, felt hot, sweating, headache), grouped into 6 domains, that provide a comprehensive evaluation of such symptoms, using 5-point scales (values ranging from 0 to 4) with higher scores indicating worse symptoms. The number of days to resolution of the selected five COVID-19 symptoms (trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and shivering), defined as a reduction in the aggregate symptom score recorded on Day 0 (prior to study drug initiation) by the FLU-PRO Plus© questionnaire to or below 5 for a minimum of three consecutive days. Flu-PRO Plus© was created and supplied by Dr. John Powers and Leidos Biomedical, and the National Institute for Allergy and Infectious Diseases (NIAID).	42 days
Secondary	Time to Resolution of COVID-19 Five Aggregated Symptoms	The number of days to resolution of five symptoms (trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and shivering), as measured by the FLU-PRO Plus© questionnaire, with resolution defined as the first aggregate symptom score of =5 which is maintained for a minimum of three consecutive days, with no individual symptom score >1	42 days
Secondary	Number of Subjects Who Had an COVID-19 Five Aggregated Symptoms Score >5 at Baseline Who Experienced Symptom Resolution as of Day 10	Resolution, defined as the first score of =5 which was maintained for a minimum of three consecutive days (without subsequent relapse), for the aggregate five COVID-19 symptoms (trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and shivering) and for each individual symptom, defined as a score of 0 or 1, as measured by the FLU-PRO Plus© questionnaire as of Day 10	10 days
Secondary	Proportion of Subjects Who Had an COVID-19 Five Aggregated Symptoms Score >5 at Baseline Who Experienced Symptom Resolution as of Day 10	Resolution, defined as the first score of =5 which was maintained for a minimum of three consecutive days (without subsequent relapse), for the aggregate five COVID-19 symptoms (trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and shivering) and for each individual symptom, defined as a score of 0 or 1, as measured by the FLU-PRO Plus© questionnaire as of Day 10.; Logistic regression with treatment as the main effect, and baseline aggregate symptom score, baseline 25D level, and body weight as covariates.	10 days
Secondary	Number of Participants With Emergency Room/Urgent Care Visits	Number and percentage of subjects with emergency room/urgent care visits	42 days
Secondary	Number of Participants With Oxygen Saturation Below 94% (Without Supplemental Oxygen)	Number and percentage of subjects with oxygen saturation below 94% (without supplemental oxygen)	42 days
Secondary	Number of Participants With Hospitalizations	Number and percentage of subjects with hospitalization	42 days
Secondary	Number of Participants With the Requirement for Mechanical Ventilation	Number and percentage of subjects requiring mechanical ventilation	42 days
Secondary	Number of Participant Deaths	Number and percentage of subjects who died	42 days
Secondary	Severity of COVID-19 Illness as Evidenced by Quality of Life Measures Using the FLU-PRO Plus Questionnaire	Quality-of-Life (QOL) responses are based on the number of non-missing observations within individual QOL question and visit. Comparisons to baseline are assessed only for subjects who were at risk for improvement. Percentages for the comparisons to baseline are based on the number at-risk for improvement.	14 days
Secondary	Resolution of Symptoms Based on FLU-PRO Plus© COVID-19 Five Symptom Aggregate Score Based on Serum 25D Level Over the Treatment Period	Clinical course of COVID-19 as a function of Serum Total 25-hydroxyvitamin D concentrations of <50 ng/mL, 50 to 100 ng/mL and >100 ng/mL at Day 14, defined as the proportion of subjects in each treatment group with a total score of =5 for the selected five COVID-19 symptoms (trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and shivering) using the FLU-PRO Plus© questionnaire. Results were similar for comparisons between treatment groups on Days 7, 14, 21 and 28, and only data for Day 14 is presented.	14 days